top of page

The Science: Complimentary Treatments
StiRx currently has a primary focus on development of long-acting gonococcal mAb (STX-426) and gonococcal vaccine (STX-428), with a chlamydia bsAb (STX-288) and other STI treatments in the exploratory phase of research.

Treatment as adjunctive therapy for repeat gonorrhea infections. For high-risk patients, potential use as long-acting immuno-prophylaxis.

Disease prevention in
all at-risk patient populations
bottom of page